Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Physicians have been left ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...